Organovo Holdings Past Earnings Performance
Past criteria checks 0/6
Organovo Holdings has been growing earnings at an average annual rate of 8.7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 42.8% per year.
Key information
8.7%
Earnings growth rate
19.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -42.8% |
| Return on equity | -210.0% |
| Net Margin | -19,160.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?
Feb 10
Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation
Aug 24We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely
May 10We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely
Jan 04Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside
May 28Revenue & Expenses Breakdown
How Organovo Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -14 | 9 | 0 |
| 31 Mar 24 | 0 | -15 | 10 | 0 |
| 31 Dec 23 | 0 | -19 | 10 | 0 |
| 30 Sep 23 | 0 | -19 | 10 | 0 |
| 30 Jun 23 | 0 | -18 | 10 | 0 |
| 31 Mar 23 | 0 | -17 | 9 | 0 |
| 31 Dec 22 | 2 | -12 | 9 | 0 |
| 30 Sep 22 | 2 | -12 | 9 | 0 |
| 30 Jun 22 | 2 | -12 | 10 | 0 |
| 31 Mar 22 | 2 | -11 | 10 | 0 |
| 31 Dec 21 | 0 | -12 | 6 | 0 |
| 30 Sep 21 | 0 | -11 | 6 | 0 |
| 30 Jun 21 | 0 | -17 | 12 | 0 |
| 31 Mar 21 | 0 | -17 | 13 | 0 |
| 31 Dec 20 | 0 | -17 | 13 | 0 |
| 30 Sep 20 | 0 | -18 | 19 | 0 |
| 30 Jun 20 | 2 | -15 | 14 | 0 |
| 31 Mar 20 | 2 | -19 | 14 | 0 |
| 31 Dec 19 | 3 | -23 | 18 | 0 |
| 30 Sep 19 | 3 | -26 | 13 | 0 |
| 30 Jun 19 | 3 | -26 | 13 | 0 |
| 31 Mar 19 | 3 | -27 | 15 | 0 |
| 31 Dec 18 | 4 | -27 | 16 | 0 |
| 30 Sep 18 | 4 | -28 | 18 | 0 |
| 30 Jun 18 | 4 | -32 | 20 | 0 |
| 31 Mar 18 | 5 | -35 | 21 | 0 |
| 31 Dec 17 | 4 | -38 | 22 | 0 |
| 30 Sep 17 | 4 | -40 | 23 | 0 |
| 30 Jun 17 | 4 | -40 | 23 | 0 |
| 31 Mar 17 | 4 | -38 | 22 | 0 |
| 31 Dec 16 | 4 | -36 | 21 | 0 |
| 30 Sep 16 | 3 | -37 | 22 | 0 |
| 30 Jun 16 | 2 | -39 | 23 | 0 |
| 31 Mar 16 | 1 | -39 | 22 | 0 |
| 31 Dec 15 | 1 | -38 | 22 | 0 |
| 30 Sep 15 | 1 | -35 | 20 | 0 |
| 30 Jun 15 | 1 | -32 | 19 | 0 |
| 31 Mar 15 | 1 | -30 | 18 | 0 |
| 31 Dec 14 | 0 | -29 | 18 | 0 |
| 30 Sep 14 | 0 | -27 | 16 | 0 |
| 30 Jun 14 | 0 | -29 | 14 | 0 |
| 31 Mar 14 | 0 | -26 | 13 | 0 |
| 31 Dec 13 | 0 | -35 | 12 | 0 |
Quality Earnings: ONVO is currently unprofitable.
Growing Profit Margin: ONVO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ONVO is unprofitable, but has reduced losses over the past 5 years at a rate of 8.7% per year.
Accelerating Growth: Unable to compare ONVO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ONVO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: ONVO has a negative Return on Equity (-209.95%), as it is currently unprofitable.